French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX)...
Hence then, the article about volitionrx participates in launch of detecseps program in france was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( VolitionRx Participates in Launch of DETECSEPS Program in France )
Also on site :
- Insider One Introduces Agent One™, the Self-Optimizing Intelligence System for Autonomous Customer Engagement
- Chunghwa Telecom Receives Frost & Sullivan's 2026 Taiwanese Customer Value Leadership Recognition for AI-Powered Customer Services
- Pricey affair! Is NSE's valuation premium to global peers justified?